磷酸氯喹和阿比多爾首次被納入抗病毒治療,石藥(1093.HK)等多家公司可關注
格隆匯2月19日丨國家衞健委、國家中醫藥管理局今日下發《新型冠狀病毒肺炎診療方案(試行第六版)》。在這一最新版的診療方案中,磷酸氯喹和阿比多爾首次被納入抗病毒治療中。據格隆匯獲悉,港股市場中涉及磷酸氯喹的公司有白雲山(0874.HK)、上海醫藥(2607.HHK)、石藥集團(1093.HK)和同方康泰(1312.HK);涉及阿比多爾的港股公司有石四藥(2005.HK)和石藥集團(1093.HK)。欲瞭解更多標的公司,可上格隆匯APP在主題頁面搜索。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.